Inventory of precautions when using cartegravir injection

Cabotegravir injection (Cabotegravir) is the first FDA approved HIV pre-exposure prophylaxis Long-acting injectable preparations provide a new option for preventing HIV-1 virus infection for adults and adolescents weighing at least 35kg. Clinical trial data shows that when used correctly, the drug is 99% effective in preventing the spread of the virus, which is undoubtedly good news for those who want to prevent HIV through non-daily medication.

There are several important considerations to keep in mind before using canegravir injection. First, a negative HIV test is required before starting treatment, a vital step to ensure the effectiveness of the drug and prevent the development of drug resistance. This step is not only responsible for oneself, but also a contribution to public health.

In addition, the advantage of cartegravir injection is its long-acting nature, which can reduce the need for daily adherence to medication and provide consistent drug levels for long-term protection. However, this does not mean that it should be used casually or that its potential risks should be ignored. Although injectable preparations are convenient, they may also cause some specific side effects, such as pain, redness and swelling at the injection site. Therefore, patients need to pay close attention to their body reactions during use and seek medical advice in time if they feel unwell.

At the same time, it is worth noting that cartegravir injection may have higher efficacy in some groups, but this also means that not everyone is suitable for use. Therefore, before use, be sure to consult a professional doctor and decide whether to use this drug based on your specific situation and the doctor's advice. In short, to use cartegravir injection correctly, you need to follow the doctor's instructions, pay attention to testing, and pay close attention to the body's reaction to ensure that it exerts the best preventive effect.

Reference link:https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212887s007lbl.pdf